Matrix controlled diffusion drug delivery systems based on one or more silicone-containing monomers of the general formula: wherein x, y, m, m', R, R1, R2, R3, R4, R5, R6, R7, X, Z and Z' are as defined herein are provided, wherein the matrix controlled diffusion drug delivery systems are sized a
Matrix controlled diffusion drug delivery systems based on one or more silicone-containing monomers of the general formula: wherein x, y, m, m', R, R1, R2, R3, R4, R5, R6, R7, X, Z and Z' are as defined herein are provided, wherein the matrix controlled diffusion drug delivery systems are sized and configured for back of the eye delivery.
대표청구항▼
What is claimed is: 1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a polymerization product of a monomeric mixture comprising one or more silicone-containing monomers of the general formu
What is claimed is: 1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a polymerization product of a monomeric mixture comprising one or more silicone-containing monomers of the general formula: wherein x and y are independently integers from 0 to about 300; m and m' are independently integers from 1 to about 6, R is independently a straight or branched, substituted or unsubstituted, C1-C30 alkyl group, a C1-C30 fluoroalkyl group, an ether or polyether containing group or a C1-C30 alkylamide group, R1, R2, R3, R4, R5, R6 and R7 are independently hydrogen, a straight or branched C1-C30 alkyl group, a C1-C30 fluoroalkyl group, a C1-C20 ester group, an alkyl ether, cycloalkyl ether, cycloalkylalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether or polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C1-C30 alkoxy group, a substituted or unsubstituted C3-C30 cycloalkyl group, a substituted or unsubstituted C3-C30 cycloalkylalkyl group, a substituted or unsubstituted C3-C30 cycloalkenyl group, a substituted or unsubstituted C5-C30 aryl group, a substituted or unsubstituted C5-C30 arylalkyl group, a substituted or unsubstituted C5-C30 heteroaryl group, a substituted or unsubstituted C3-C30 heterocyclic ring, a substituted or unsubstituted C4-C30 heterocyclolalkyl group, a substituted or unsubstituted C6-C30 heteroarylalkyl group, fluorine, a vinyl group, a C5-C30 fluoroaryl group, or a hydroxyl group; X is independently a straight or branched C1-C30 alkyl group, a C1-C30 fluoroalkyl group, a substituted or unsubstituted C5-C30 arylalkyl group, a substituted or unsubstituted C1-C30 alkoxy group, an ether, polyether, sulfide, or amino containing group and Z and Z' are independently a polymerizable ethylenically unsaturated organic radical, wherein the matrix controlled diffusion drug delivery system is sized and configured for back of the eye delivery. 2. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R1, R2, R3, R4, R5, R6 and R7 are independently a straight or branched C1-C30 alkyl group, and Z and Z' are selected from an ester or amide of acrylic or methacrylic acid. 3. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R1, R2, R3, R4, R5, R6 and R7 are independently a straight or branched C1-C6 alkyl group X is a bond or an ether or polyether containing group, and Z and Z' are independently an ester or amide of acrylic or methacrylic acid. 4. The matrix controlled diffusion drug delivery system of claim 1, wherein x is 2 to about 100, y is 2 to about 100, R is independently a straight or branched C1-C30 fluoroalkyl group, an alkyl ether or polyether group or a straight or branched C 1-C30 alkylamide group, R1, R2, R3, R4, R5, R6 and R7 are independently a straight or branched C1-C6 alkyl group, X is independently a bond or one or more C1-C30 alkyl ether groups or polyether groups and Z and Z' are independently an ester or amide of acrylic or methacrylic acid. 5. The matrix controlled diffusion drug delivery system of claim 1, wherein the one or more pharmaceutically active agents is selected from the group consisting of an anti-glaucoma agent, anti-cataract agent, anti-diabetic retinopathy agent, thiol cross-linking agent, anti-cancer agent, immune modulator agent, anti-clotting agent, anti-tissue damage agent, anti-inflammatory agent, anti-fibrous agent, non-steroidal anti-inflammatory agent, antibiotic, anti-pathogen agent, piperazine derivative, cycloplegic agent, miotic agent, mydriatic agent and mixtures thereof. 6. The matrix controlled diffusion drug delivery system of claim 1, wherein the one or more pharmaceutically active agents is selected from the group consisting of an anticholinergic, anticoagulant, antifibrinolytic, antihistamine, antimalarial, antitoxin, chelating agent, hormone, immunosuppressive, thrombolytic, vitamin, protein, salt, desensitizer, prostaglandin, amino acid, metabolite, antiallergenic and mixtures thereof. 7. The matrix controlled diffusion drug delivery system of claim 1, wherein the monomeric mixture comprises one or more other monomers or prepolymers. 8. The matrix controlled diffusion drug delivery system of claim 7, wherein the one or more monomers are selected from the group consisting of methyl methacrylate, 2-ethylhexyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, dimethyl itaconate, trifluoromethyl methacrylate, hexafluoroisopropyl methacrylate, bis(hexafluoroisopropyl) methacrylate, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, acrylic acid, itaconic acid, acrylic anhydride, methacrylic anhydride, maleic anhydride, itaconic anhydride, glycerol methacrylate, hydroxypropyl methacrylate, N,N-dimethylacrylamide, acrylamide, N-methylacrylamide, N-vinylpyrrolidione, N-isopropylacrylamide, hydroxybutyl methacrylate and mixtures thereof. 9. The matrix controlled diffusion drug delivery system of claim 1, in a form of a solution, suspension, solution/suspension, microsphere or nanosphere. 10. The matrix controlled diffusion drug delivery system of claim 1, in a form of a semi-solid or solid article suitable for ocular implant.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Mueller Karl F. (New York NY), Dimethylacrylamide-copolymer hydrogels with high oxygen permeability.
Mueller Karl F. (New York NY) Heiber Sonia J. (Bedford Hills NY) Plankl Walter L. (Yorktown Heights NY), Strong, silicone containing polymers with high oxygen permeability.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.